Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(48 sites)

United States

Banner MD Anderson Cancer Center ( Site 0152), Gilbert, Arizona

Northside Hospital-Northside Hospital Oncology Network ( Site 0156), Atlanta, Georgia

Parkview Research Center at Parkview Regional Medical Center ( Site 0180), Fort Wayne, Indiana

Baptist Health Lexington-Research ( Site 0158), Lexington, Kentucky

University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0157), Lexington, Kentucky